Jim Trenkle, Ph.D., MBA
Board member
Dr. Trenkle has over 15 years of experience in R&D, commercialization, and early-stage biotech investing and transactions. He joined Novo Ventures (US) Inc. as a Partner in May 2022. Prior to joining Novo, he was Head of Investments at Sanofi Ventures in Cambridge, MA, where he was responsible for a team making investments into private US-based therapeutics life science companies. Prior to Sanofi, he was Vice President of Investments with Pivotal bioVenture Partners in San Francisco. He began his career with Gilead Sciences where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy, largely focused on hepatitis C and other liver diseases.
Dr. Trenkle completed a B.S. in Honors Chemistry at University of Michigan, a Ph.D. in Organic Chemistry at Massachusetts Institute of Technology and holds an M.B.A. from University of California Berkeley, Haas School of Business.
